Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to June 19, 2022
Public Health Ontario (this document is updated regularly so you will see a later version than the one I am referring to in this post which is for June 19, 2022 — accessed July 3, 2022)
This report provides a summary of adverse events following immunization (AEFIs) that are temporally associated (i.e., occur after receiving the vaccine) with receipt of COVID-19 vaccine and meet the provincial surveillance definitions (i.e., confirmed). It is important to note that AEFIs described in this report are defined as any untoward medical occurrences that followed immunization and do not necessarily have a causal relationship with the vaccine.
This summary includes AEFIs reported in the Public Health Case and Contact Management Solution (CCM) as of June 19, 2022. Doses administered up to and including June 19, 2022 are extracted from the Ontario Ministry of Health’s COVaxON application (see technical notes for details on data sources). The report is updated on a bi-weekly basis
The Background paragraph (page 1) provides several resources for more information, including:
- “The government of Canada’s COVID-19 vaccine safety webpage for national data on COVID-19 vaccine safety”: https://health-infobase.canada.ca/covid-19/vaccine-safety/
- “PHO’s COVID-19 vaccine webpage for resources and data on Ontario’s COVID-19 vaccine program”: https://www.publichealthontario.ca/en/diseases-and-conditions/infectious-diseases/respiratory-diseases/novel-coronavirus/vaccines
There are a total of 20,867 AEFI reports received following 32,882,531 doses of COVID-19 vaccines administered in Ontario to date with a reporting rate of 63.5 per 100,000 doses administered (0.06% of all doses administered) (Page 1)
Note: I believe that very few of the actual adverse reactions from the CV-19 get reported. I believe we’re in a situation where there is plenty of resistance from medical professionals and public health authorities. There is too much intimidation, fear and effective propaganda. I’m just making use of the data provided.
See one of the Data Caveats on page 16:
Data presented in this report only represent AEFIs reported to public health units and recorded in CCM. As a result, all counts will be subject to varying degrees of reporting bias, including underreporting . . . .
Note the following point under Methods to avoid confusion:
Each AEFI report refers to an individual who reported an adverse event after receiving a dose of COVID-19 vaccine. An AEFI report may contain multiple adverse events. Therefore, the total number of adverse events can exceed the number of individual AEFI reports reported in a given time frame. . . .
Social engineering nonsense, coming from the same people pushing the CV narrative, corrupts this report:
On October 14, 2021 changes were made in CCM to enable reporting on Sex and Gender separately; previously, sex and gender were reported interchangeably under the Gender field. Male/Female information presented in this report are sourced from the Sex field in CCM and are intended to represent sex assigned at birth. The doses administered data from the COVaxON application are presented by gender, which is used as a proxy for doses administered by sex in calculating sex-specific reporting rates.
Other points under Methods:
Serious AEFIs are defined using the World Health Organization (WHO) standard definition: an AEFI that results in death, is life-threatening, requires in-patient hospitalization or prolongs an existing hospitalization, results in persistent or significant disability/incapacity, or in a congenital anomaly/birth defect. Due to data limitations and the relatively brief follow-up period of AEFIs reported in Ontario, AEFI reports that meet the serious definition typically have an in-patient hospitalization or death reported. In-patient hospitalization is defined as having a hospital admission recorded in CCM. Deaths are defined as reporting ‘fatal’ in the outcome field in CCM.
I think the distinction of “Serious AEFI” is just a way to minimize the seriousness of many of the other adverse events being reported. Look at this other term they use: “Medically Important”:
Some selected adverse events can be defined as “medically important,” based on the World Health Organization’s (WHO) guidance, regardless of whether they meet the serious AEFI definition. These types of events may jeopardize the patient or may require intervention to prevent an outcome described in the serious definition (e.g., hospitalization); “medically important” events may be defined after applying medical and scientific judgement. In Ontario, the specific events under surveillance that align with this definition include: acute disseminated encephalomyelitis (ADEM), events managed as anaphylaxis, encephalitis/encephalopathy, Guillain-Barré syndrome (GBS), intussusception, meningitis, myelitis/transverse myelitis and thrombocytopenia
Adverse Events of Special Interest (AESI):
Several adverse events of special interest (AESI) following administration of COVID-19 vaccine(s) were selected for surveillance. These are: vaccine-associated enhanced disease, multisystem inflammatory syndrome in children and adults, acute respiratory distress syndrome, acute cardiovascular injury, myocarditis/pericarditis, coagulation disorder (including thrombotic events), thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombotic thrombocytopenia (VITT), acute kidney injury, acute liver injury, anosmia and/or ageusia, chilblain-like lesions, single organ cutaneous vasculitis, erythema multiforme, acute pancreatitis, rhabdomyolysis, and subacute thyroiditis.
Going back to Highlights:
Of the total 20,867 AEFI reports received to date:
- 19,696 AEFI reports are non-serious (94.4% of total AEFI reports)
- 1,171 AEFI reports meet the serious definition (5.6% of total AEFI reports
. . .
- 774 reports of myocarditis or pericarditis after receipt of mRNA vaccine . . .
In Ontario, AEFIs that meet the serious definition are events that required hospital admission and reports of death. (p. 2)
A note on page 4 mentions the Canadian Immunization Guide for COVID-19 vaccines: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a8.3.
I don’t detect the terms “miscarriage,” “stillbirth,” or “abortion” in this document, which is suspicious to me.
There are various tables and they refer to six vaccine products, with Pfizer counted twice, so five of the six CV-19 vaccine products approved for Canada so far are listed, but not Medicago Covifenz:
- Pfizer-BioNTech Comirnaty pediatric COVID-19 vaccine (10 mcg)
- Pfizer-BioNTech Comirnaty COVID-19 vaccine (30 mcg)
- Moderna Spikevax COVID-19 vaccine
- AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine
- Janssen (Johnson & Johnson) COVID-19 vaccine
- Novavax Nuvaxovoid COVID-19 vaccine
Figure 2 (page 9) shows “Ten most frequently reported adverse events for all COVID-19 vaccines: Ontario, December 13, 2020 to June 19, 2022”
(The full list is at the bottom of this post)
- Other severe or unusual events [Think of how many conditions are excluded from being explicitly mentioned by using this category] (between 5500 and 6000)
- Allergic skin reactions (between 4000 and 5000)
- Pain/redness/swelling at the injection site (between 3500 and 4000)
- Rash (between 2000 and 2500)
- Anaesthesia/paraesthesia (between 1500 and 2000)
- Adenopathy/lymphadenopathy (between 1000 and 1500)
- Arthritis/arthralgia (about 1000)
- Severe vomiting/diarrhea (just under 1000)
- Fever in conjunction with another reportable event (just under 1000)
- AESI – Myocarditis/pericarditis (between 500 and 1000)
The ‘other severe or unusual events’ category includes reports of adverse events that do not meet any other pre-defined events outlined in the Infectious Diseases Protocol: Appendix1 but are assessed to be clinically important or epidemiologically interesting. These events usually require medical attention but do not necessarily meet either the medically important event definition or the serious AEFI definition. . . . (p. 10)
There were 679 reports with medically important events, representing 3.3% of all reports. The 679 reports include 517 reports of events managed as anaphylaxis, of which 38 met the definition of a serious AEFI. Of all 517 reports of events managed as anaphylaxis: 468 received epinephrine, 450 were seen in the emergency department and 389 were fully recovered at the time of reporting. . . .(p. 10)
Absurdly, only 38 of those were classified as “serious”!
The Public Health Agency of Canada (PHAC) and Health Canada are actively monitoring reports of GBS [Guillain-Barré syndrome] following AstraZeneca Vaxzevria COVID-19 vaccination and have observed a higher number of cases than would normally be expected in the general population. In Ontario, 41 reports of GBS have been reported to date, including 17 following AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine . . . (p. 10)
In the discussion on AESI’s (explained above):
In Ontario, 10 reports of multisystem inflammatory syndrome in children and adults (MIS-C/A) have been reported to date, including 8 following Pfizer-BioNTech Comirnaty COVID-19 vaccine and 2 following Moderna Spikevax COVID-19 vaccine. . . . (p. 10 as of June 19, 2022 document)
Update: July 9, 2022 – continuing with the June 19, 2022 version of the document. Note that later versions are likely to be similar
THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS) AND VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA (VITT)
Thrombosis with Thrombocytopenia Syndrome (TTS) is a condition characterized by the presence of acute venous or arterial thrombosis with new onset thrombocytopenia (low levels of platelets), and no known recent exposure to heparin. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) refers to the clinical syndrome of TTS, in addition to laboratory tests that confirm platelet activation (i.e., anti-platelet 4 antibodies). VITT has been reported following immunization with COVID-19 adenoviral vector vaccines, including AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine. Out of an abundance of caution [!?] due to an observed increase in reports of TTS/VITT in Ontario, the province announced [https://news.ontario.ca/en/statement/1000103/ontario-pauses-administration-of-astrazeneca-vaccine] a pause on the administration of first doses of the AstraZeneca Vaxzevria COVID-19 vaccine on May 11, 2021. More information on TTS and VITT can be found on PHO’s Synthesis on COVID-19 Viral Vector Vaccines and Rare [!?] Blood Clots [https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/07/covid-19-viral-vector-vaccines-rare-blood-clots.pdf?sc_lang=en] and Ontario’s COVID-19 Science Advisory Table scientific briefs on Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination [See https://covid19-sciencetable.ca/brief-category/infectious-diseases-clinical-care/ and specific document: https://covid19-sciencetable.ca/sciencebrief/vaccine-induced-immune-thrombotic-thrombocytopenia-vitt-following-adenovirus-vector-covid-19-vaccination/].
To date, there have been 21 reports of TTS following the first dose of AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine in Ontario (including one probable TTS); of these, 16 are confirmed as VITT [Vaccine-Induced Immune Thrombotic Thrombocytopenia] with positive anti-PF4 antibody test results. . . . The most recent event had a vaccination date of May 6, 2021. There has been one report of death recorded in CCM in an individual with VITT. A Coroner’s investigation determined that the immediate causes of death included Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). . . .
There have been international reports, including from the United States and Israel, of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines. Information to date indicates that these events occur more commonly after the second dose, within the week following vaccination (typically within 4-5 days), mainly in adolescents/young adults and more often in males than females.
Vaccine safety surveillance data in Canada suggest relatively higher rates of myocarditis/pericarditis reported after Moderna Spikevax COVID-19 vaccine compared to Pfizer-BioNTech Comirnaty COVID-19 vaccine. Similar trends have been observed in Ontario’s vaccine safety data where the reporting rates of myocarditis/pericarditis was observed to be higher following vaccination with Moderna Spikevax COVID-19 vaccine compared to Pfizer-BioNTech Comirnaty COVID-19 vaccine in the 18 to 24 year old age group, particularly among males. Out of an abundance of caution[!?], Ontario issued a preferential recommendation of the use of Pfizer-BioNTech Comirnaty COVID-19 vaccine for individuals aged 18 to 24 year olds on September 29, 2021 and later expanded this to individuals aged 12 to 29 years of age to align with the updated NACI recommendation [the National Advisory Committee on Immunization: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html]. Ontario is continuing to monitor these events in collaboration with its partners and updates can be found within this report and on the PHAC website. For more information on this topic please see PHO’s Focus On: Myocarditis and Pericarditis after COVID-19 mRNA Vaccines and additional in-depth analysis in Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario: December 13, 2020 to November 21, 2021.
As of June 19, 2022, there have been 774 reports of myocarditis or pericarditis following receipt of COVID-19 mRNA vaccines in Ontario. These reports have been identified through case-level review of all reported AEFIs. Of these, 203 (26.2%) were diagnosed with myocarditis and 371 (47.9%) were diagnosed with pericarditis. The remaining 200 (25.8%) were diagnosed with perimyocarditis (n=37), myopericarditis (n=152) and myocarditis/pericarditis (n=11). . . .
The most recent in-depth analysis of myocarditis/pericarditis meeting the Brighton Collaboration case definition is available in Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario: December 13, 2020 to November 21, 2021.
In Ontario, AEFIs that meet the serious definition are events that required hospital admission and reports of death . . . .
There were 1,171 AEFI reports classified as serious, representing 5.6% of all AEFI reports and a serious AEFI reporting rate of 3.6 per 100,000 doses administered for all vaccine products combined. Of the 1,171 reports meeting the serious definition, 1,144 reports had a hospital admission related to the adverse event and 27 were reports of deaths. . . .
Again, I think this is a way to generate smaller numbers and get the readers to focus on them, minimizing whatever else is happening in the overall reporting of AEFIs (Adverse Events Following Immunization).
AEFI REPORTS REQUIRING HOSPITALIZATION
Of the 1,144 reports of hospitalization, 447 were recovered at the time of reporting, 511 were not yet recovered when the investigation was completed but likely to recover, and 100 reported persistent or significant disability/incapacity related to the adverse event. . . .
AEFI REPORTS WITH FATAL OUTCOME
In Ontario, reports of death that meet the provincial AEFI surveillance case definition [see https://www.health.gov.on.ca/en/pro/programs/publichealth/oph_standards/docs/aefi_chapter.pdf] are those that are temporally associated with vaccination, where no other clear cause of death can be established. Similar to other events, reports of deaths are thoroughly investigated by the local PHU through the collection of relevant information including a cause of death (e.g., autopsy or Coroner’s report). It is important to note that these reports should not be interpreted as causally related with receipt of a vaccine.
As of June 19, 2022, there are 27 reports of death temporally associated with receipt of COVID-19 vaccine that met the provincial surveillance case definition. There was one death where AEFI may have been a contributing factor of death; in this death, a Coroner’s investigation determined that the immediate causes of death included VITT.
. . .
I don’t believe those numbers for deaths. I think that many people, including doctors, are unwilling to associate deaths with the vaccines because of the climate of propaganda, intimidation and corruption (i.e., media and government induced cultism and also criminality which needs to be prosecuted). Therefore many deaths are not being reported. Also, PHO’s case definition system probably whittles down the number of deaths they accept as “temporally associated” with vaccination. The same applies to hospitalizations and to many of the other adverse events. Most are probably not getting associated with the vaccines and are not getting reported.
Table 4 has a geographical breakdown of the number of adverse events reported in each public health unit and region in Ontario (page 14).
There are various technical notes, some of which we quoted already. There are also many references at the end, which have other information.
Table A1 in Appendix A is:
Number of AEFI reports by adverse event and vaccine product: Ontario, December 13, 2020 to June 19, 2022
I am just listing the numbers for all the COVID-19 vaccine products combined:
- Other severe or unusual events: 5,780
- Allergic skin reactions: 4,710
- Pain/redness/swelling at the injection site: 3,682
- Rash: 2,235
- Anaesthesia/paraesthesia: 1,763
- Adenopathy/lymphadenopathy: 1,133 [swelling of glands / lymph nodes]
- Arthritis/arthralgia: 996
- Severe vomiting/diarrhea: 963
- Fever in conjunction with another reportable event: 956
- AESI – Myocarditis [inflammation of the heart]/pericarditis: 776
- Event managed as anaphylaxis: 516 [life-threatening allergic reaction]
- AESI – Coagulation disorder (including thrombotic events): 406 [blood clots]
- Syncope (fainting) with injury: 331
- Bell’s Palsy: 322 [facial paralysis]
- Cellulitis: 277 [potentially serious bacterial skin infection]
- AESI – Acute cardiovascular injury: 221
- Convulsions/seizure: 162
- thrombocytopenia: 86 [low blood platelet count]
- Nodule: 85
- Paralysis: 47
- AESI – Anosmia, ageusia: 43 [loss of sense of smell/taste]
- Guillain-Barré syndrome (GBS): 41 [“rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system”]
- AESI – Acute liver injury 37
- AESI – TTS [thrombosis with thrombocytopenia syndrome] /VITT [vaccine-induced immune thrombotic thrombocytopenia] 28
- Oculorespiratory syndrome (ORS) 27
- AESI – Acute kidney injury 26
- Myelitis/transverse myelitis: 21 [inflammation of the spinal cord]
- AESI – Subacute thyroiditis: 20
- AESI – Single organ cutaneous vasculitis: 19 [inflamed blood vessels in the skin]
- AESI – Chilblain-like lesions: 18
- AESI – Acute pancreatitis: 14
- AESI – Rhabdomyolysis: 14 [“serious medical condition . . . damaged muscle tissue releases its proteins and electrolytes into the blood”]
- AESI – Erythema multiforme: 14 [target-like skin lesions on the hands]
- Encephalopathy/encephalitis: 12 [brain disease / inflammation]
- AESI – multisystem inflammatory syndrome in children/adults: 10 [“different body parts become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs” – note how the CDC says this is “associated with COVID-19” (https://www.cdc.gov/mis/index.html)]
- Infected abscess: 8
- Parotitis: 6 [inflammation of the salivary glands]
- AESI – Acute respiratory distress syndrome: 4
- Sterile abscess: 4
- Meningitis: 3 [“acute or chronic inflammation of the protective membranes covering the brain and spinal cord”]
- Acute disseminated encephalomyelitis (ADEM): 2 [“sudden, widespread attack of inflammation in the brain and spinal cord”]
- Kawasaki Disease: 1 [“blood vessels become inflamed throughout the body”]
(The notes for Table A1 include an explanation of different points, including that the “number of reports with ‘AESI – Myocarditis/pericarditis’ presented in this table is based on CCM data entry and may be different from the number of myocarditis or pericarditis reports that are presented in the Myocarditis/Pericarditis section, which is based on case-level review.”)
Table A2 shows the reporting rate per 100,000 doses for each condition.
Table A3 presents the myocarditis/pericarditis reporting rates for different categories.
Read through the above list of adverse events and tell me why it isn’t criminal to make people take these injections.
I’m sure the actual numbers are much higher than these, but nevertheless, 27 deaths is not a small number. 47 cases of paralysis doesn’t seem small to me. 331 cases of fainting doesn’t seem like a small number either. 963 cases of severe vomiting/diarrhea doesn’t seem like a minor thing. Neither does 37 cases of acute liver injury nor does 26 cases of acute kidney injury. The various types of brain inflammation seem like a major problem. 162 cases of convulsions/seizure is not a small number. 221 cases of acute cardiovascular injury seems like a lot. So do 41 cases of Guillain-Barré syndrome. Same with all the cases of blood clotting, heart inflammation, skin inflammation and spinal cord inflammation. 14 cases of acute pancreatitis is crazy. And so on. These are just what has been reported and filtered. Note there are 5,780 “other severe or unusual events” and what are all of these supposed to be? Could they include stillbirths as reported by Ontario MPP Rick Nicholls? Are these “vaccines” really for “public health”?